オハイオにおける小細胞肺がんの臨床試験
オハイオ内の拠点で、小細胞肺がんに関する28件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center /ID# 277556, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07155174Prospective Multiomic Analysis in Small-Cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中観察研究
18歳以上 · 全性別 · 2026/10/02更新 · NCT07795411The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07226999A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Canton
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07099898DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Oncology Hematology Care - Fairfield /ID# 280641, Fairfield
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07365241Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07278479A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07325136A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Cleveland Clinic - Akron General Medical Center, Akron
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic - Fairview Hospital Molly Pavilion, Cleveland
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Oncology Hematology Care, Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06646276Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Cleveland Clinic - Akron General Hematology & Oncology, Akron
- Cleveland Clinic Mercy Hospital Cancer Center, Canton
- The Christ Hospital Cancer Center, Cincinnati
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT06712355Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- Ohio State Univerity, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07057791A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06892548A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Oncology Hematology Care Clinical Trials, Cincinnati
- University Hospital - Cleveland Medical Center, Cleveland
- Zangmeister Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Cleveland Clinic Mercy Hospital, Canton
- Oncology/Hematology Care Clinical Trials, Llc, Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/06更新 · NCT06203210Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/06更新 · NCT07423585A Study of LY4175408 in Participants With Advanced Cancer
- The Ohio State University (OSU) Wexner Medical Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- TriHealth Cancer Institute, Cincinnati
- Ohio State University, Columbus
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/15更新 · NCT05257551Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Cleveland Clinic, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/08更新 · NCT05363280Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/08更新 · NCT04919382Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Aultman Health Foundation, Canton
- Miami Valley Hospital South, Centerville
- Miami Valley Hospital, Dayton
- 他5件
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/30更新 · NCT06769126Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
- Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
被験者募集中第1/2相
18歳〜80歳 · 全性別 · 2025/12/11更新 · NCT03556228A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/23更新 · NCT06805825A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
- Zelgen Site 101, Canton
- Zelgen Site 104, Cleveland
被験者募集中第1相
18歳〜75歳 · 全性別 · 2025/08/06更新 · NCT06592638ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。